In tumor cells, the expression of Gal-9 differs by tumor type, showing reduced levels in hepatocellular carcinoma, prostate cancer, colorectal cancer, cervical cancer, and skin cancer [86–89]. Here, LGALS9 is linked to prostate cancer.